Immatics N.V.
IMTX$1.34B
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaTUBINGEN645 employees
Drugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
7wMarket Overview
Stock performance and key metrics
IMTX News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
IMA203
Melanoma, Cutaneous Malignant
Sunitinib
Metastatic Renal Cell Carcinoma
IMA402 (Phase Ia)
Refractory Cancer
Endoxana, Leukine, IMA910
Colorectal Carcinoma
IMA203 Product
Refractory Cancer
Endoxana, IMA901, Leukine
Renal Cell Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMA203 | Phase 3 | Melanoma, Cutaneous Malignant | - | - |
Sunitinib | Phase 3 | Metastatic Renal Cell Carcinoma | - | - |
IMA402 (Phase Ia) | Phase 2 | Refractory Cancer | - | - |
Endoxana, Leukine, IMA910 | Phase 2 | Colorectal Carcinoma | - | - |
IMA203 Product | Phase 2 | Refractory Cancer | - | - |
Endoxana, IMA901, Leukine | Phase 2 | Renal Cell Carcinoma | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply